Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)

Next Previous
X
Search
Trial Profile

Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Apr 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Romidepsin (Primary) ; Teropavimab (Primary) ; Antiretrovirals
  • Indications HIV-1 infections
  • Focus Pharmacodynamics
  • Acronyms eCLEAR

    • Most Recent Events

    • 01 Nov 2022 Results(n=55) assessing Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1 published in the Nature Medicine
    • 16 Feb 2022 Results of an analysis assessing whether a vaccinal effect also occurs in humans, measured HIV-1-specific T cell immune responses in newly diagnosed HIV-1-infected individuals starting antiretroviral therapy with or without the potent bNAb 3BNC117 presented at the 29th Conference on Retroviruses and Opportunistic Infections
    • 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top